Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn’s Disease

 Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn’s Disease

Lilly Reports Results of Mirikizumab in P-ll SERENITY Study for Crohn’s Disease

Shots:

  • The P-ll SERENITY study involves the assessing of Mirikizumab (200mg, 600mg, 1000mg) vs PBO in patients in the ratio of 2:1:1:2 with moderately to severely active CD. The P-II study includes 12wks. induction period and 40wks. continued treatment period, evaluating the safety and efficacy of multiple dosing regimens and two methods of administration @52wks.
  • Result: @52wks. ~60% achieved endoscopic responses (58.5% in IV dosing group and 58.7% in the SC group) while 45% + achieved PRO remission (46.3% in the IV group and 45.6% in the SC group), presented at UEG Week 2020
  • Mirikizumab is a humanized IgG4 mAb that binds to the P19 subunit of interleukin 23 and being studied for the treatment of immune diseases, including psoriasis, UC, & CD

    Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Bless Ayurveda

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post